Synthesis and pharmacological evaluation of nucleoside prodrugs designed to target siderophore biosynthesis in Mycobacterium tuberculosis.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 26875934)

Published in Bioorg Med Chem on February 03, 2016

Authors

Surendra Dawadi1, Shuhei Kawamura1, Anja Rubenstein1, Rory Remmel1, Courtney C Aldrich2

Author Affiliations

1: Department of Medicinal Chemistry, University of Minnesota, Minneapolis, MN 55455, United States.
2: Department of Medicinal Chemistry, University of Minnesota, Minneapolis, MN 55455, United States. Electronic address: aldri015@umn.edu.

Articles cited by this

Prodrugs: design and clinical applications. Nat Rev Drug Discov (2008) 3.16

Small-molecule inhibition of siderophore biosynthesis in Mycobacterium tuberculosis and Yersinia pestis. Nat Chem Biol (2005) 2.55

Rationally designed nucleoside antibiotics that inhibit siderophore biosynthesis of Mycobacterium tuberculosis. J Med Chem (2006) 2.37

Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers. Nat Protoc (2007) 1.98

Inhibition of aryl acid adenylation domains involved in bacterial siderophore synthesis. FEBS J (2006) 1.61

The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells. Nat Rev Microbiol (2014) 1.46

Heterogeneity in tuberculosis pathology, microenvironments and therapeutic responses. Immunol Rev (2015) 1.45

Antitubercular nucleosides that inhibit siderophore biosynthesis: SAR of the glycosyl domain. J Med Chem (2006) 1.41

Inhibition of siderophore biosynthesis in Mycobacterium tuberculosis with nucleoside bisubstrate analogues: structure-activity relationships of the nucleobase domain of 5'-O-[N-(salicyl)sulfamoyl]adenosine. J Med Chem (2008) 1.40

5'-O-[(N-acyl)sulfamoyl]adenosines as antitubercular agents that inhibit MbtA: an adenylation enzyme required for siderophore biosynthesis of the mycobactins. J Med Chem (2007) 1.39

Prodrugs of nucleoside analogues for improved oral absorption and tissue targeting. J Pharm Sci (2008) 1.25

A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis. Bioorg Med Chem Lett (2013) 1.25

Pharmacokinetic and in vivo efficacy studies of the mycobactin biosynthesis inhibitor salicyl-AMS in mice. Antimicrob Agents Chemother (2013) 0.97

Development of a selective activity-based probe for adenylating enzymes: profiling MbtA Involved in siderophore biosynthesis from Mycobacterium tuberculosis. ACS Chem Biol (2012) 0.94

Synthesis, pH-dependent, and plasma stability of meropenem prodrugs for potential use against drug-resistant tuberculosis. Bioorg Med Chem (2013) 0.88

Identification of esterases expressed in Caco-2 cells and effects of their hydrolyzing activity in predicting human intestinal absorption. Drug Metab Dispos (2005) 0.85

Pivalate-generating prodrugs and carnitine homeostasis in man. Pharmacol Rev (2002) 0.82

Synthesis and Pharmacokinetic Evaluation of Siderophore Biosynthesis Inhibitors for Mycobacterium tuberculosis. J Med Chem (2015) 0.82

Synthesis of chromone, quinolone, and benzoxazinone sulfonamide nucleosides as conformationally constrained inhibitors of adenylating enzymes required for siderophore biosynthesis. J Org Chem (2013) 0.81

Investigation and conformational analysis of fluorinated nucleoside antibiotics targeting siderophore biosynthesis. J Org Chem (2015) 0.79

Evaluation of transport mechanism of prodrugs and parent drugs formed by intracellular metabolism in Caco-2 cells with modified carboxylesterase activity: temocapril as a model case. J Pharm Sci (2011) 0.78